A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy
- 10 June 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 31 (7), 1423-1434
- https://doi.org/10.1681/asn.2020010081
Abstract
Cardiac hypertrophy is a common feature in patients with CKD. Recent studies revealed that two phosphate regulators, fibroblast growth factor-23 and α-Klotho, are highly involved in the pathophysiologic process of CKD-induced cardiac hypertrophy. With decreasing renal function, elevated fibroblast growth factor-23 and decreased α-Klotho may contribute to cardiac hypertrophy by targeting the heart directly or by inducing systemic changes, such as vascular injury, hemodynamic disorders, and inflammation. However, several studies have demonstrated that disturbances in the fibroblast growth factor-23/α-Klotho axis do not lead to cardiac hypertrophy. In this review, we describe the cardiac effects of the fibroblast growth factor-23/α-Klotho axis and summarize recent progress in this field. In addition, we present not only the main controversies in this field but also provide possible directions to resolve these disputes.Keywords
Funding Information
- National Natural Science Foundation of China (81270825, 81770727)
- Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017)
- Science and Technology Planning Project of Guangdong Province (2017A010103041)
- Key Project of Guangzhou Science Technology and Innovation Commission (201804020054)
This publication has 121 references indexed in Scilit:
- Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate dietKidney International, 2012
- βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and MetabolismCell Metabolism, 2012
- Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heartNature Communications, 2012
- Transforming growth factor (TGF)-β signaling in cardiac remodelingJournal of Molecular and Cellular Cardiology, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney diseaseKidney International, 2010
- Klotho is a substrate for α‐, β‐ and γ‐secretaseFEBS Letters, 2009
- Amelioration of the premature ageing‐like features of Fgf‐23 knockout mice by genetically restoring the systemic actions of FGF‐23The Journal of Pathology, 2008
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006